This inventor holds 3 USPTO granted patents. Top assignee: Mitsui Toatsu Chemicals, Incorporated. Active years: 1981.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 1981
Title: The Innovations of Toshio Suganuma: A Contributor to Cephalosporin Development
Introduction
Toshio Suganuma, an accomplished inventor based in Mobara, Japan, has made significant contributions to the field of pharmaceuticals, specifically in the development of cephalosporins. With a total of three patents to his name, his work reflects a commitment to advancing medical science through innovative solutions.
Latest Patents
Suganuma's latest patents focus on specific formulations of cephalosporanic acid. His first patent describes a cephalosporanic acid of the general formula wherein A represents a defined structure, along with its pharmaceutically acceptable salts and esters. The second patent outlines a similar formulation, with Y representing either a hydrogen atom or a hydroxyl group, including its biologically acceptable salts and esters. These contributions underscore his expertise in developing effective pharmaceutical compounds.
Career Highlights
Toshio Suganuma is currently employed at Mitsui Toatsu Chemicals, Incorporated, where he utilizes his knowledge and skills in medicinal chemistry to foster innovation. His career reflects a dedication to research and development in the pharmaceutical industry.
Collaborations
Suganuma has collaborated with several esteemed colleagues, including Akira Matsubara and Hideaki Sakai. These partnerships have facilitated the exchange of ideas and expertise, contributing to the advancement of their collective work in the pharmaceutical domain.
Conclusion
In conclusion, Toshio Suganuma's contributions to the field of cephalosporins through his inventions and patents reflect his role as a significant figure in pharmaceutical innovations. His work not only impacts the industry but also enhances the potential for new therapeutic solutions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
